Natural products as a source of Coronavirus entry inhibitors
The COVID-19 pandemic has had a significant and lasting impact on the world. Four years on, despite the existence of effective vaccines, the continuous emergence of new SARS-CoV-2 variants remains a challenge for long-term immunity. Additionally, there remain few purpose-built antivirals to protect...
| Main Authors: | , , , |
|---|---|
| Format: | Journal Article |
| Language: | English |
| Published: |
Frontiers Media
2024
|
| Subjects: | |
| Online Access: | http://hdl.handle.net/20.500.11937/95243 |
| _version_ | 1848765990935986176 |
|---|---|
| author | Szabó, Dávid Crowe, Andrew Mamotte, Cyril Strappe, Padraig |
| author_facet | Szabó, Dávid Crowe, Andrew Mamotte, Cyril Strappe, Padraig |
| author_sort | Szabó, Dávid |
| building | Curtin Institutional Repository |
| collection | Online Access |
| description | The COVID-19 pandemic has had a significant and lasting impact on the world. Four years on, despite the existence of effective vaccines, the continuous emergence of new SARS-CoV-2 variants remains a challenge for long-term immunity. Additionally, there remain few purpose-built antivirals to protect individuals at risk of severe disease in the event of future coronavirus outbreaks. A promising mechanism of action for novel coronavirus antivirals is the inhibition of viral entry. To facilitate entry, the coronavirus spike glycoprotein interacts with angiotensin converting enzyme 2 (ACE2) on respiratory epithelial cells. Blocking this interaction and consequently viral replication may be an effective strategy for treating infection, however further research is needed to better characterize candidate molecules with antiviral activity before progressing to animal studies and clinical trials. In general, antiviral drugs are developed from purely synthetic compounds or synthetic derivatives of natural products such as plant secondary metabolites. While the former is often favored due to the higher specificity afforded by rational drug design, natural products offer several unique advantages that make them worthy of further study including diverse bioactivity and the ability to work synergistically with other drugs. Accordingly, there has recently been a renewed interest in natural product-derived antivirals in the wake of the COVID-19 pandemic. This review provides a summary of recent research into coronavirus entry inhibitors, with a focus on natural compounds derived from plants, honey, and marine sponges. |
| first_indexed | 2025-11-14T11:44:02Z |
| format | Journal Article |
| id | curtin-20.500.11937-95243 |
| institution | Curtin University Malaysia |
| institution_category | Local University |
| language | eng |
| last_indexed | 2025-11-14T11:44:02Z |
| publishDate | 2024 |
| publisher | Frontiers Media |
| recordtype | eprints |
| repository_type | Digital Repository |
| spelling | curtin-20.500.11937-952432024-08-06T02:21:55Z Natural products as a source of Coronavirus entry inhibitors Szabó, Dávid Crowe, Andrew Mamotte, Cyril Strappe, Padraig COVID-19 SARS-CoV-2 antiviral coronavirus entry inhibitor fusion inhibitor natural product Humans Animals Biological Products Pandemics COVID-19 Disease Outbreaks HIV Fusion Inhibitors Animals Humans Biological Products HIV Fusion Inhibitors Disease Outbreaks Pandemics COVID-19 The COVID-19 pandemic has had a significant and lasting impact on the world. Four years on, despite the existence of effective vaccines, the continuous emergence of new SARS-CoV-2 variants remains a challenge for long-term immunity. Additionally, there remain few purpose-built antivirals to protect individuals at risk of severe disease in the event of future coronavirus outbreaks. A promising mechanism of action for novel coronavirus antivirals is the inhibition of viral entry. To facilitate entry, the coronavirus spike glycoprotein interacts with angiotensin converting enzyme 2 (ACE2) on respiratory epithelial cells. Blocking this interaction and consequently viral replication may be an effective strategy for treating infection, however further research is needed to better characterize candidate molecules with antiviral activity before progressing to animal studies and clinical trials. In general, antiviral drugs are developed from purely synthetic compounds or synthetic derivatives of natural products such as plant secondary metabolites. While the former is often favored due to the higher specificity afforded by rational drug design, natural products offer several unique advantages that make them worthy of further study including diverse bioactivity and the ability to work synergistically with other drugs. Accordingly, there has recently been a renewed interest in natural product-derived antivirals in the wake of the COVID-19 pandemic. This review provides a summary of recent research into coronavirus entry inhibitors, with a focus on natural compounds derived from plants, honey, and marine sponges. 2024 Journal Article http://hdl.handle.net/20.500.11937/95243 10.3389/fcimb.2024.1353971 eng http://creativecommons.org/licenses/by/4.0/ Frontiers Media fulltext |
| spellingShingle | COVID-19 SARS-CoV-2 antiviral coronavirus entry inhibitor fusion inhibitor natural product Humans Animals Biological Products Pandemics COVID-19 Disease Outbreaks HIV Fusion Inhibitors Animals Humans Biological Products HIV Fusion Inhibitors Disease Outbreaks Pandemics COVID-19 Szabó, Dávid Crowe, Andrew Mamotte, Cyril Strappe, Padraig Natural products as a source of Coronavirus entry inhibitors |
| title | Natural products as a source of Coronavirus entry inhibitors |
| title_full | Natural products as a source of Coronavirus entry inhibitors |
| title_fullStr | Natural products as a source of Coronavirus entry inhibitors |
| title_full_unstemmed | Natural products as a source of Coronavirus entry inhibitors |
| title_short | Natural products as a source of Coronavirus entry inhibitors |
| title_sort | natural products as a source of coronavirus entry inhibitors |
| topic | COVID-19 SARS-CoV-2 antiviral coronavirus entry inhibitor fusion inhibitor natural product Humans Animals Biological Products Pandemics COVID-19 Disease Outbreaks HIV Fusion Inhibitors Animals Humans Biological Products HIV Fusion Inhibitors Disease Outbreaks Pandemics COVID-19 |
| url | http://hdl.handle.net/20.500.11937/95243 |